title: Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
abstract: Pegylated liposomal doxorubicin (PLD) is usually used in disseminated HIV-related Kaposi's sarcoma (KS). It is the first-line treatment or second-line therapy in patients who do not tolerate or do not respond to polychemotherapy since 1995, when it was approved by the FDA. We report two cases of disseminated classic KS not associated with immunosuppression in which HHV-8 infection was demonstrated. They showed an excellent response to PLD, with good tolerance and an absence of side effects.
authors.affiliation: Department of Dermatology, Hospital Juan Canalejo, La Coruña, Spain. iria.cm@canalejo.org
authors.forename: Iria
authors.initials: I
authors.lastname: Castiñeiras
authors.forename: Manuel
authors.initials: M
authors.lastname: Almagro
authors.forename: Jesús
authors.initials: J
authors.lastname: Rodríguez-Lozano
authors.forename: Beatriz
authors.initials: B
authors.lastname: Fernández-Jorge
authors.forename: Sabela
authors.initials: S
authors.lastname: Paradela
authors.forename: Jesús Del
authors.initials: JD
authors.lastname: Pozo
authors.forename: Eduardo
authors.initials: E
authors.lastname: Fonseca
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000188:drug therapy* / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000903:Antibiotics, Antineoplastic; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin